Meta‐analysis: The impact of light‐to‐moderate alcohol consumption on progressive non‐alcoholic fatty liver disease
Alimentary Pharmacology & Therapeutics · 2023
DOI: 10.1111/apt.17388 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2023. Verfasst von Louise Magherman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology Research Unit, Dpt. Internal Medicine and Pediatrics, Liver Research Center Ghent, Ghent University, Ghent, Belgium. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Fonds Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
Background and Aims Non‐alcoholic fatty liver disease (NAFLD) is defined as fatty liver disease in the absence of heavy alcohol consumption. However, the impact of light‐to‐moderate alcohol consumption on progressive NAFLD and on mortality is presently unclear.
Methods
Medline, Embase, OATD and OpenGrey were systematically searched up to November 2022 for relevant cross‐sectional, case–control and cohort studies. The study outcomes were progressive NAFLD—steatohepatitis (NASH), fibrosis, cirrhosis, hepatocellular carcinoma (HCC) and mortality. The entire review process was performed by two independent reviewers. A narrative synthesis was performed for all outcomes, while meta‐analyses, subgroup analyses and publication bias assessment were performed depending on the number of articles.
Results
After study selection, 32 articles were included. Cohort studies reported that moderate alcohol intake increased the risk for advanced fibrosis (pooled OR 1.56; 95% CI 1.08–2.26 and HR 1.39; 95% CI 1.22–1.57), which was not observed in cross‐sectional studies. Alcohol use also increased the risk of developing liver cirrhosis and HCC, but seemed to lower the risk of steatohepatitis. Light alcohol consumption protected against all‐cause mortality, an effect not observed in NAFLD patients with moderate intake.
Conclusions
There is wide heterogeneity in studies on the impact of alcohol on progressive NAFLD. Nevertheless, cohort studies reported a significant harmful effect of moderate alcohol consumption on the occurrence of advanced fibrosis. Further research is needed to make valid recommendations with regard to alcohol consumption in patients with NAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Hepatology Research Unit, Dpt. Internal Medicine and Pediatrics, Liver Research Center Ghent, Ghent University, Ghent, Belgium.
- Knowledge Center for Health Ghent, Ghent University and Ghent University Hospital, Ghent, Belgium.
- Gut-Liver Immunopharmacology Unit, Department of Basic and Applied Medical Sciences, Liver Research Center Ghent, Ghent University, Ghent, Belgium.
ORCID-Profile: Lindsey Devisscher, Hans Van Vlierberghe, Anja Geerts, Sander Lefere
Förderung
- Fonds Wetenschappelijk Onderzoek
Zitieren
APA
Magherman, L., Van Parys, R., Pauwels, N. S., Verhelst, X., Devisscher, L., Van Vlierberghe, H., Geerts, A., & Lefere, S. (2023). Meta‐analysis: The impact of light‐to‐moderate alcohol consumption on progressive non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17388
Vancouver
Magherman L, Van Parys R, Pauwels NS, Verhelst X, Devisscher L, Van Vlierberghe H, et al. Meta‐analysis: The impact of light‐to‐moderate alcohol consumption on progressive non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17388
BibTeX
@article{Magherman2023,
author = {Magherman, Louise and Van Parys, Robbe and Pauwels, Nele S and Verhelst, Xavier and Devisscher, Lindsey and Van Vlierberghe, Hans and Geerts, Anja and Lefere, Sander},
title = {Meta‐analysis: The impact of light‐to‐moderate alcohol consumption on progressive non‐alcoholic fatty liver disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
doi = {10.1111/apt.17388}
}
EUVIMED